Overview

Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients

Status:
Unknown status

Trial end date:
2018-02-28

Target enrollment:
0

Participant gender:
All

Summary

It has been observed that despite administration of apparently adequate thyroid hormone replacement in hypothyroid patients, many of them experience persistent fatigue and fatigue-related symptoms. Carnitine transports long chain fatty acids into the mitochondria whereupon the high energy source (ATP) becomes synthesized. Levocarnitine administration reduced fatigue related symptoms in hypothyroid patients receiving thyroid hormone replacement. The present study deals with alleviation of fatigue in hypothyroid patients by carnitine supplementation.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Criteria

Inclusion Criteria:

i. Clinical diagnosis of primary hypothyroidism patients with fatigue symptoms ii. Age :
From 20 to 50 years iii. Levothyroxine treatment: receiving for at least 6 months iv. Serum
free thyroxine level: 0.80-1.80 ng/dl v. Serum Thyroid-stimulating hormone level: 0.35-5.50
µIU/ml ( µIU = micro international unit)

-

Exclusion Criteria:

i. Patients with Hypothyroidism 20 years and 50 years ii. Acute or chronic liver diseases
iii. Anaemia iv. Clinical diagnosis of Diabetes mellitus. v. Cardiovascular disease ( such
as heart failure, arrhythmia and uncontrolled hypertension ) vi. Patients with
psychological disorders (such as depression, anxiety disorder, schizophrenia, alcoholism or
fatigue disorder due to other systemic diseases) vii. Patients having serious infections or
terminal illness (such as tuberculosis, HIV or malignant tumor ) viii. Autoimmune diseases
( such as rheumatoid arthritis, Systemic lupus erythematosus or multiple sclerosis) ix.
Patients with impaired renal function x. Pregnant or planned to be pregnant xi. Nursing
mothers

-